| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ebola haemorrhagic fever.
|
Lancet
|
2011
|
8.28
|
|
2
|
Ebola virus disease in West Africa--clinical manifestations and management.
|
N Engl J Med
|
2014
|
3.73
|
|
3
|
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
|
Sci Transl Med
|
2012
|
1.94
|
|
4
|
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
|
Lancet Infect Dis
|
2015
|
1.94
|
|
5
|
Ebola in West Africa-CDC's Role in Epidemic Detection, Control, and Prevention.
|
Emerg Infect Dis
|
2015
|
0.91
|
|
6
|
A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.
|
PLoS Negl Trop Dis
|
2016
|
0.87
|
|
7
|
Ebola Virus Infection: Overview and Update on Prevention and Treatment.
|
Infect Dis Ther
|
2015
|
0.83
|
|
8
|
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.
|
Virology
|
2015
|
0.83
|
|
9
|
Ebola virus disease candidate vaccines under evaluation in clinical trials.
|
Expert Rev Vaccines
|
2016
|
0.82
|
|
10
|
A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact.
|
Expert Rev Anti Infect Ther
|
2015
|
0.76
|
|
11
|
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.
|
N Engl J Med
|
2017
|
0.75
|